Hip Injection Trial (HIT)

  • Research type

    Research Study

  • Full title

    Improving outcomes for patients with hip osteoarthritis: a randomised controlled trial

  • IRAS ID

    163306

  • Contact name

    Jacqueline Gray

  • Contact email

    j.gray@keele.ac.uk

  • Sponsor organisation

    Keele University

  • Eudract number

    2014-003412-37

  • ISRCTN Number

    ISRCTN50550256

  • Duration of Study in the UK

    2 years, 1 months, 31 days

  • Research summary

    Hip osteoarthritis (OA) is a very common condition that causes pain and can affect ability to do day to day activities.

    There have been several studies about treatments for OA including joint injections. However, little is known about the best treatments for patients with moderate to severe hip OA.

    This trial aims to find out whether best current treatment in addition to a single steroid and local anaesthetic injection is effective at reducing pain in patients with hip OA when compared to best current treatment and a single local anasthetic injection, or best current treatment alone. We will study the effects of these 3 treatments over 6 months.

    Participants will be recruited from primary care referrals to orthopaedics, rheumatology and two musculoskeletal services in Staffordshire. Patients aged 40 years and over and who have experienced pain from hip OA for at least 6 weeks will be eligible for inclusion.

    The steroid is a drug called "Triamcinolone Acetonide". This drug is widely used to treat joint pain and arthritis. In this trial, one injection will be given at one time point. Each participant will receive either best current treatment and a single steroid and local anaesthetic injection, best current treatment and a local anaesthetic injection, or best current treatment alone. Participants will be asked to complete up to 5 questionnaires over 6 months.

  • REC name

    North West - Greater Manchester South Research Ethics Committee

  • REC reference

    15/NW/0546

  • Date of REC Opinion

    27 Jul 2015

  • REC opinion

    Further Information Favourable Opinion